Abstract:. Presented at the 2026 World Conference on Lung Cancer, two phase III trials—PAPILLON and REZILIENT3—established amivantamab and zipalertinib combination therapies as effective first-line ...
Abstract. B cells and their cellular neighborhoods, i.e., lymphoid aggregates (LAs) and tertiary lymphoid structures (TLS), have not been extensively studied in melanoma brain metastases (BM) or lung ...
AbstractBackground:. Wildfires are becoming more frequent and severe, reversing decades of progress in reducing fine particulate matter (PM2.5) in the United States. Although wildfire smoke (WFS) ...
13Huntsman Cancer Institute, Salt Lake City, UT.
Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, ...
JNJ-95437446 is a potential best-in-class EGFR/MET bispecific antibody drug conjugate designed to deliver a cytotoxic payload to tumor cells while leveraging the unique characteristics of amivantamab.
BigHat Biosciences, Inc., San Mateo, CA.
Abstract. Recurrent glioblastoma (rGBM) is an aggressive brain tumor with median survival under one year after standard chemoradiation. Antigen heterogeneity, immune exclusion, and a suppressive tumor ...
SciBrunch Therapeutics Co., Ltd, Shanghai, China.
Cancer Discov (2026) 16 (4): 670–676.
You do not currently have access to this content.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results